Join
Live feed
·
PRReleasevia Quantisnow
Cytokinetics Incorporated logo

Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

ByQuantisnow·Wall Street's wire, on your screen.
CYTK· Cytokinetics Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CYTK (Cytokinetics Incorporated) and more on Quantisnow.